LILRA2 anticorps (C-Term)

N° du produit ABIN6258958

Détail du produit anti-LILRA2 anticorps

Antigène: LILRA2 (Leukocyte Immunoglobulin-Like Receptor, Subfamily A (With TM Domain), Member 2 (LILRA2))

Épitope: C-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp LILRA2 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Specificité: LILRA2 Antibody detects endogenous levels of total LILRA2.

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human LILRA2, corresponding to a region within C-terminal amino acids.

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:1000, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline , pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20 °C. Stable for 12 months from date of receipt.

Date de péremption: 12 months

Détails sur LILRA2

Antigène: LILRA2 (Leukocyte Immunoglobulin-Like Receptor, Subfamily A (With TM Domain), Member 2 (LILRA2))

Autre désignation: LILRA2 (LILRA2 Produits)

Synonymes: anticorps CD85H, anticorps ILT1, anticorps LIR-7, anticorps LIR7, anticorps leukocyte immunoglobulin like receptor A2, anticorps LILRA2

Sujet:

Description: Part of the innate immune responses against microbial infection (PubMed:12529506, PubMed:27572839). Specifically recognizes a set of N-terminally truncated immunoglobulins that are produced via cleavage by proteases from a range of pathogenic bacteria and fungi, including L.pneumophila, M.hyorhinis, S.pneumoniae, S.aureus and C.albicans (PubMed:27572839). Recognizes epitopes that are in part in the variable region of the immunoglobulin light chains, but requires also the constant region for signaling (PubMed:27572839). Binds to a subset of cleaved IgM, IgG3 and IgG4 Molecules, but does not bind cleaved IgA1 (PubMed:27572839). Binding of N-terminally truncated immunoglobulins mediates activation of neutrophils (PubMed:27572839). In monocytes, activation leads to the release of CSF2, CF3, IL6, CXCL8 and CCL3 and down-regulates responses to bacterial lipopolysaccharide (LPS), possibly via down-regulation of TLR4 expression and reduced signaling via TLR4 (PubMed:22479404). In eosinophils, activation by ligand binding leads to the release of RNASE2, IL4 and leukotriene C4 (PubMed:12529506). Does not bind class I MHC antigens (PubMed:19230061).

Gene: LILRA2

Poids moléculaire: 53 kDa

ID gène: 11027

UniProt: Q8N149